{"id":251048,"date":"2022-03-17T00:00:00","date_gmt":"2022-03-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/exinim0006-2022-biopharma-inflammatory-myositis-executive-insights\/"},"modified":"2026-04-15T23:20:07","modified_gmt":"2026-04-15T23:20:07","slug":"exinim0006-2022-biopharma-inflammatory-myositis-executive-insights-inflammatory-myositis-executive-insights-us-eu5","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exinim0006-2022-biopharma-inflammatory-myositis-executive-insights-inflammatory-myositis-executive-insights-us-eu5\/","title":{"rendered":"Inflammatory Myositis &#8211; Executive Insights &#8211; Inflammatory Myositis: Executive Insights | US\/EU5 | 2022"},"content":{"rendered":"<p>Inflammatory myositis (<abbr title=\"inflammatory myositis\">IM<\/abbr>) is a heterogeneous group of autoimmune disorders characterized by immune-mediated muscle injury that results in muscle inflammation and skeletal muscle weakness. Corticosteroids, steroid-sparing agents, and other immunosuppressive drugs are the mainstay for the management of <abbr title=\"inflammatory myositis\">IM<\/abbr>. In 2021, Octagam 10% (IVIg) was approved for the treatment of dermatomyositis in the United States and Europe. Targeted assets with novel mechanisms of action (<abbr title=\"monoclonal antibody\">MAb<\/abbr>, <abbr title=\"Janus-activated kinase\">JAK<\/abbr> inhibitor, <abbr title=\"cytotoxic T-lymphocyte-associated antigen\">CTLA<\/abbr>-4 agonist, CB2 agonist) are in late-phase development for the treatment of <abbr title=\"inflammatory myositis\">IM<\/abbr>. Major unmet needs, including limited approved therapies for <abbr title=\"inflammatory myositis\">IM<\/abbr>, present a lucrative commercial opportunity and could drive the future market dynamics.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the diagnosed prevalence of <abbr title=\"inflammatory myositis\">IM<\/abbr>?<\/li>\n<li>What is the current market landscape including the diagnostic and management practices across different markets under study?<\/li>\n<li>What is the potential impact of pipeline therapies, and how will these therapies affect future <abbr title=\"inflammatory myositis\">IM<\/abbr> market dynamics?<\/li>\n<li>What are the key unmet needs and areas of opportunity in the management of <abbr title=\"inflammatory myositis\">IM<\/abbr>?<\/li>\n<li>What are the key drivers and limiters of the <abbr title=\"inflammatory myositis\">IM<\/abbr> market?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.<\/p>\n<p><strong>Geography:<\/strong> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr><\/p>\n<p><strong>Primary research:<\/strong> 13 <abbr title=\"key opinion leader\">KOL<\/abbr> interviews from November 2021 to January 2022<\/p>\n<p><strong>Key companies covered:<\/strong> Octapharma, <abbr title=\"Bristol Myers Squibb\">BMS<\/abbr>, CSL Behring, Corbus Pharmaceuticals, Alexion, Pfizer, Kezar Life Sciences, others<\/p>\n<p><strong>Key drugs covered: <\/strong>Octagam, Orencia, Hizentra, lenabasum, Ultomiris, PF-06823859, KZR-616, others<\/p>\n","protected":false},"template":"","class_list":["post-251048","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatology","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251048\/revisions"}],"predecessor-version":[{"id":283492,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251048\/revisions\/283492"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}